tetano
Editor, Senior Moderator
Am J Ther
. 2022 Aug 19.
doi: 10.1097/MJT.0000000000001543. Online ahead of print.
Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review
Effat Davoudi-Monfared[SUP] 1 [/SUP], Arezoo Ahmadi[SUP] 2 [/SUP], Elahe Karimpour-Razkenari[SUP] 1 [/SUP], Bita Shahrami[SUP] 1 [/SUP], Farhad Najmeddin[SUP] 1 [/SUP], Mojtaba Mojtahedzadeh[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Remdesivir (RDV) is the main antiviral for the treatment of moderate to severe forms of Coronavirus disease 2019 (COVID-19). Several studies revealed a shortening time to clinical improvement of COVID-19 and mortality benefits in patients receiving RDV. The patients with renal disease were excluded from large clinical trials of RDV, and the probable nephrotoxicity of the drug, its metabolites, and the vehicle (sulfobutylether-β-cyclodextrin) have led to the recommendation against using RDV in patients with an estimated glomerular filtration rate of <30 mL/min.
Areas of uncertainty: This systematic review aimed to collect data about the necessity and safety administration of RDV in the setting of renal impairment.
Data sources: Search through databases including MEDLINE, ScienceDirect, Cochrane Library, and PubMed was performed. The studies were carried out in adults and enrolled patients with different types of renal impairment (ie, acute kidney injury, chronic kidney disease, kidney transplant, and renal replacement therapy) were included. Eligible studies were assessed, and required data were extracted.
Results: Twenty-two cross-sectional studies, cohorts, case reports, and case series were included in this review. The mortality rate was between 7.3% and 50%, and various severity of COVID-19 was included in the studies. None of them reported an increase in adverse effects attributed to RDV administration. A decrease in inflammatory mediators and other benefits were obvious.
Conclusions: Although the manufacturer's labeling does not recommend RDV administration in patients with severe renal impairment, it seems that nephrotoxicity is less concerning in the population of these patients. Moreover, RDV may be helpful in acute kidney injury induced by the viral invasion of COVID-19. To the best of our knowledge, this is the first systematic review of the use of RDV in kidney failure. Larger, well-designed, and pharmacokinetic studies are required to have a safe and logical recommendation about the use of RDV in patients with renal disorders.
. 2022 Aug 19.
doi: 10.1097/MJT.0000000000001543. Online ahead of print.
Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review
Effat Davoudi-Monfared[SUP] 1 [/SUP], Arezoo Ahmadi[SUP] 2 [/SUP], Elahe Karimpour-Razkenari[SUP] 1 [/SUP], Bita Shahrami[SUP] 1 [/SUP], Farhad Najmeddin[SUP] 1 [/SUP], Mojtaba Mojtahedzadeh[SUP] 1 [/SUP]
Affiliations
- PMID: 35984955
- DOI: 10.1097/MJT.0000000000001543
Abstract
Background: Remdesivir (RDV) is the main antiviral for the treatment of moderate to severe forms of Coronavirus disease 2019 (COVID-19). Several studies revealed a shortening time to clinical improvement of COVID-19 and mortality benefits in patients receiving RDV. The patients with renal disease were excluded from large clinical trials of RDV, and the probable nephrotoxicity of the drug, its metabolites, and the vehicle (sulfobutylether-β-cyclodextrin) have led to the recommendation against using RDV in patients with an estimated glomerular filtration rate of <30 mL/min.
Areas of uncertainty: This systematic review aimed to collect data about the necessity and safety administration of RDV in the setting of renal impairment.
Data sources: Search through databases including MEDLINE, ScienceDirect, Cochrane Library, and PubMed was performed. The studies were carried out in adults and enrolled patients with different types of renal impairment (ie, acute kidney injury, chronic kidney disease, kidney transplant, and renal replacement therapy) were included. Eligible studies were assessed, and required data were extracted.
Results: Twenty-two cross-sectional studies, cohorts, case reports, and case series were included in this review. The mortality rate was between 7.3% and 50%, and various severity of COVID-19 was included in the studies. None of them reported an increase in adverse effects attributed to RDV administration. A decrease in inflammatory mediators and other benefits were obvious.
Conclusions: Although the manufacturer's labeling does not recommend RDV administration in patients with severe renal impairment, it seems that nephrotoxicity is less concerning in the population of these patients. Moreover, RDV may be helpful in acute kidney injury induced by the viral invasion of COVID-19. To the best of our knowledge, this is the first systematic review of the use of RDV in kidney failure. Larger, well-designed, and pharmacokinetic studies are required to have a safe and logical recommendation about the use of RDV in patients with renal disorders.